Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Magnesium Sulfate in Mesothelioma, Malignant: NCT04481672 Clinical Landscape Report 2026
28 September 2026
NCT04481672 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BZDS-1901 in Mesothelin positive Solid Tumors: NCT04489862 Clinical Landscape Report 2026
28 September 2026
NCT04489862 clinical landscape for Mesothelin positive Solid Tumors: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Gemcitabine Hydrochloride in Advanced Bile Duct Carcinoma: NCT04491942 Clinical Landscape Report 2026
28 September 2026
NCT04491942 clinical landscape for Advanced Bile Duct Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Mesothelioma, Malignant: NCT04515836 Clinical Landscape Report 2026
28 September 2026
NCT04515836 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Unresectable Pleural Malignant Mesothelioma: NCT04665206 Clinical Landscape Report 2026
28 September 2026
NCT04665206 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
ATA-2271 in Malignant Mesothelioma of Peritoneum: NCT04577326 Clinical Landscape Report 2026
28 September 2026
NCT04577326 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Poly ICLC in Malignant Pleural Mesothelioma: NCT04525859 Clinical Landscape Report 2026
28 September 2026
NCT04525859 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Itraconazole in Renal Medullary Carcinoma: NCT04537715 Clinical Landscape Report 2026
28 September 2026
NCT04537715 clinical landscape for Renal Medullary Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Microsatellite instability-high colorectal cancer: NCT04802876 Clinical Landscape Report 2026
28 September 2026
NCT04802876 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Viltolarsen in Muscular Dystrophy, Duchenne: NCT04687020 Clinical Landscape Report 2026
28 September 2026
NCT04687020 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Golodirsen in Muscular Dystrophy, Duchenne: NCT04708314 Clinical Landscape Report 2026
28 September 2026
NCT04708314 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Malignant Pleural Mesothelioma: NCT04713761 Clinical Landscape Report 2026
28 September 2026
NCT04713761 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.